KURZPROTOKOLL
C-Patrol

Öffentlicher Titel	Nicht interventionelle Studie zu Olaparib bei Ovarialkarzinompatienten mit BRCAm+ und PSR
Wissenschaftl. Titel	A Single Arm, Prospective Non-interventional Study (NIS) to Collect Clinical and Patient Reported Outcome Data in an Olaparib Treated BRCAm+ PSR Ovarian Cancer Population
Kurztitel	C-Patrol
Studienart	multizentrisch, prospektiv, offen/unverblindet, einarmig, Pharma-Studie
Studienphase	nicht zutreffend
Erkrankung	Geschlechtsorgane: Krebserkrankungen der weiblichen Geschlechtsorgane: Eierstockkrebs (Ovarialkarzinom) - Zweitlinie oder höher
Einschlusskriterien	- Signed written informed consent prior to or at day 1 of olaparib treatment - Women aged >= 18 years - Patients with platinum sensitive relapsed high grade epithelial ovarian cancers (including primary peritoneal and/or fallopian tube cancer). (Platinum sensitive disease is defined as disease progression 6 months after completion of their last dose of platinum based chemotherapy. Patients must be currently in response to platinum-based chemotherapy. For the last chemotherapy course immediately prior to enrolment on the study, patients must be, in the opinion of the investigator, in response (partial or complete), following completion of this chemotherapy course. - Documented BRCA mutations (germline and/or somatic mutation in BRCA1 (Breast Cancer gene 1) and/or BRCA2 (Breast Cancer gene 2) that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function)) - Patients should be in line with the specifications mentioned in the German LYNPARZA (olaparib) SmPC (Summary Product Characteristics)
Ausschlusskriterien	- Known hypersensitivity to olaparib or any of the excipients of the drug - Patients who have started olaparib monotherapy for more than 14 days before giving their informed consent - Pregnancy or breast feeding
Alter	18 Jahre und älter
Molekularer Marker	BRCA
Prüfzentren	**Frauenheilkunde und Geburtshilfe** (Rekrutierung beendet) Theodor-Stern-Kai 7 60590 Frankfurt am Main Allg. Ansprechpartner der Abteilung Gynäkologie (UCT, UKF)
Sponsor	Astra Zeneca
Förderer	Astra Zeneca
Registrierung in anderen Studienregistern	Deutsches Register Klinischer Studien DRKS00010737 ClinicalTrials.gov NCT02503436
Therapie	Olaparib